CN109085354B - 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 - Google Patents
水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 Download PDFInfo
- Publication number
- CN109085354B CN109085354B CN201810825412.7A CN201810825412A CN109085354B CN 109085354 B CN109085354 B CN 109085354B CN 201810825412 A CN201810825412 A CN 201810825412A CN 109085354 B CN109085354 B CN 109085354B
- Authority
- CN
- China
- Prior art keywords
- varicella
- antigen
- zoster virus
- recombinant expression
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 26
- 241000701085 Human alphaherpesvirus 3 Species 0.000 title claims abstract description 22
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 40
- 108091007433 antigens Proteins 0.000 claims abstract description 40
- 239000000427 antigen Substances 0.000 claims abstract description 38
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 claims abstract description 29
- 239000000243 solution Substances 0.000 claims abstract description 23
- 238000005406 washing Methods 0.000 claims abstract description 21
- 238000003259 recombinant expression Methods 0.000 claims abstract description 19
- 210000002966 serum Anatomy 0.000 claims abstract description 17
- 239000003085 diluting agent Substances 0.000 claims abstract description 12
- 241000588724 Escherichia coli Species 0.000 claims abstract description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 9
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims abstract description 8
- 239000013598 vector Substances 0.000 claims abstract description 7
- 239000012089 stop solution Substances 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 238000010367 cloning Methods 0.000 claims abstract description 4
- 239000013613 expression plasmid Substances 0.000 claims abstract description 4
- 239000013642 negative control Substances 0.000 claims abstract description 4
- 108020004705 Codon Proteins 0.000 claims abstract description 3
- 239000013604 expression vector Substances 0.000 claims abstract description 3
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 230000001131 transforming effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 9
- 229940098773 bovine serum albumin Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 238000007865 diluting Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 3
- 101710088839 Replication initiation protein Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 238000005259 measurement Methods 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 230000009871 nonspecific binding Effects 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- 230000006798 recombination Effects 0.000 abstract description 2
- 230000001808 coupling effect Effects 0.000 abstract 1
- 238000012407 engineering method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 229940021648 varicella vaccine Drugs 0.000 description 6
- 238000001976 enzyme digestion Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
观测一致率P<sub>0</sub> | 0.9864 | 标准误Se(K) | 0.015 |
期望一致率P<sub>e</sub> | 0.5975 | Kappa值 | 0.965 |
u检验 | 64.33 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810825412.7A CN109085354B (zh) | 2018-07-25 | 2018-07-25 | 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810825412.7A CN109085354B (zh) | 2018-07-25 | 2018-07-25 | 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109085354A CN109085354A (zh) | 2018-12-25 |
CN109085354B true CN109085354B (zh) | 2021-07-23 |
Family
ID=64838540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810825412.7A Active CN109085354B (zh) | 2018-07-25 | 2018-07-25 | 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109085354B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117106071B (zh) * | 2019-11-11 | 2024-08-27 | 珠海泰诺麦博制药股份有限公司 | 抗水痘-带状疱疹病毒的抗体 |
CN114150020A (zh) * | 2021-10-13 | 2022-03-08 | 中国科学技术大学 | 基于化学发光免疫分析法的vzv感染诊断检测试剂盒 |
CN117074673B (zh) * | 2023-10-18 | 2024-05-28 | 北京华诺泰生物医药科技有限公司 | 一种定量检测重组带状疱疹疫苗或/和原液比活性的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128026A2 (en) * | 2005-05-26 | 2006-11-30 | The United States Of America As Represented By Thesecretary, Dept. Of Health And Human Services National Institutes Of Health | Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus |
CN101012446A (zh) * | 2007-02-07 | 2007-08-08 | 华中农业大学 | 一种检测猪产毒多杀性巴氏杆菌毒素抗体的elisa试剂盒及应用 |
CN104360055A (zh) * | 2014-11-07 | 2015-02-18 | 山东泰邦生物制品有限公司 | 测定水痘-带状疱疹病毒中和抗体的试剂盒及生产方法 |
CN105669838A (zh) * | 2014-12-04 | 2016-06-15 | 厦门大学 | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 |
CN106279378A (zh) * | 2016-08-05 | 2017-01-04 | 北京市华信行生物科技有限公司 | 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途 |
-
2018
- 2018-07-25 CN CN201810825412.7A patent/CN109085354B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128026A2 (en) * | 2005-05-26 | 2006-11-30 | The United States Of America As Represented By Thesecretary, Dept. Of Health And Human Services National Institutes Of Health | Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus |
CN101012446A (zh) * | 2007-02-07 | 2007-08-08 | 华中农业大学 | 一种检测猪产毒多杀性巴氏杆菌毒素抗体的elisa试剂盒及应用 |
CN104360055A (zh) * | 2014-11-07 | 2015-02-18 | 山东泰邦生物制品有限公司 | 测定水痘-带状疱疹病毒中和抗体的试剂盒及生产方法 |
CN105669838A (zh) * | 2014-12-04 | 2016-06-15 | 厦门大学 | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 |
CN106279378A (zh) * | 2016-08-05 | 2017-01-04 | 北京市华信行生物科技有限公司 | 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途 |
Non-Patent Citations (1)
Title |
---|
Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay;Jian Liu 等;《Methods and protocols》;20160105;第100卷;摘要,第9321–9329页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109085354A (zh) | 2018-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113151187B (zh) | 一株非洲猪瘟病毒单克隆抗体杂交瘤细胞及其应用 | |
CN109085354B (zh) | 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法 | |
CN116023506B (zh) | Asfv非结构蛋白优势抗原表位融合蛋白及其试剂盒与应用 | |
CN112980802B (zh) | 一种分泌鸭新型呼肠孤病毒σB蛋白单抗的杂交瘤细胞、单抗及应用 | |
WO2012163263A1 (en) | Reagents and methods for prrsv detection | |
CN111474367A (zh) | 非洲猪瘟病毒p30蛋白单克隆抗体筛选和检测用试剂盒及其制备方法 | |
CN111751553A (zh) | 小反刍兽疫病毒H蛋白抗体iELISA检测方法及应用 | |
CN115073613A (zh) | 一种融合蛋白GLuc-p30及其制备方法和应用 | |
CN113461808B (zh) | 牛传染性鼻气管炎病毒的竞争elisa抗体检测试剂盒及其应用 | |
CN113943354B (zh) | 一种重组猫疱疹病毒gB蛋白抗原及其在抗体诊断和疫苗制备中的应用 | |
CN110568189B (zh) | 犬腺病毒1型抗体elisa检测试剂盒及其应用 | |
CN114807178B (zh) | 非洲猪瘟病毒p72蛋白c末端多表位重组抗原及应用 | |
CN109762052B (zh) | 猪圆环病毒3型Cap重组蛋白及其编码基因和应用 | |
CN116183913A (zh) | 一种塞内卡病毒a的抗体检测试剂盒及其应用 | |
KR101080071B1 (ko) | 재조합 n 단백질에 대한 단클론 항체를 이용한 리프트계곡열 경합적 효소결합면역측정법 | |
CN116068192A (zh) | 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用 | |
CN114150020A (zh) | 基于化学发光免疫分析法的vzv感染诊断检测试剂盒 | |
CN110161246B (zh) | 区分新城疫病毒样颗粒疫苗免疫血清与野毒感染血清的间接竞争elisa方法及试剂盒 | |
CN112180089A (zh) | 一种牛疱疹病毒i型抗体阻断elisa检测方法 | |
CN117683127B (zh) | 猪流行性腹泻病毒抗体捕获elisa检测试剂盒 | |
CN111393510A (zh) | 一种非洲猪瘟病毒重组抗原及其应用 | |
CN117886896B (zh) | 非洲猪瘟多表位重组蛋白asfvmea及应用 | |
CN114315991B (zh) | 一种基于鸭黄病毒e蛋白及其单抗的竞争elisa方法 | |
CN112444626B (zh) | 一种非洲猪瘟病毒抗体elisa检测试剂盒及其制备方法 | |
CN116790509B (zh) | 一种分泌抗猪伪狂犬病病毒gB蛋白抗体的单克隆杂交瘤细胞株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240806 Address after: No. 858 Gaoxin Avenue, Donghu Development Zone, Wuhan City, Hubei Province 430074 Patentee after: Wuhan Kangdeqing Biotechnology Co.,Ltd. Country or region after: China Address before: Floor 1-5, building B6, Wuhan National Biological Industry (Jiufeng innovation) base, 666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 Patentee before: WUHAN LIFE TECHNOLOGY Co.,Ltd. Country or region before: China |